Etravirine
- CAS No.
- 269055-15-4
- Chemical Name:
- Etravirine
- Synonyms
- CS-1948;TMC 125;R 165335;Etravirine;Etravirine Powder;Etravirine（TMC-125）;Etravirine (R165335;Etravirine 13C 15N2;4-[[6-AMino-5-broMo-2-[(4-cyanophenyl)aMino]-4-pyriMidinyl]oxy]-3,5-diMethyl -;4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile
- CBNumber:
- CB51509336
- Molecular Formula:
- C20H15BrN6O
- Molecular Weight:
- 435.28
- MOL File:
- 269055-15-4.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/29 17:07:33
| Melting point | .265°C (dec.) |
|---|---|
| Boiling point | 637.4±65.0 °C(Predicted) |
| Density | 1.439 g/cm3 |
| storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| solubility | DMSO (Slightly), Methanol (Slightly, Heated, Sonicated) |
| form | Solid |
| pka | 1.23±0.10(Predicted) |
| color | White to Off-White |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H410 | |||||||||
| Precautionary statements | P273-P391-P501 | |||||||||
| NFPA 704 |
|
Etravirine price More Price(1)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | 901779 | 4-((6-Amino-5-bromo-2-((4-cyanophenyl)amino)pyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrile | 269055-15-4 | 100MG | ₹11517.8 | 2022-06-14 | Buy |
| Product number | Packaging | Price | Buy |
|---|---|---|---|
| 901779 | 100MG | ₹11517.8 | Buy |
Etravirine Chemical Properties,Uses,Production
Description
Etravirine is a second-generation NNRTI. It is indicated for use in
combination with other antiretroviral agents for treating HIV-1 infection in
treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to the currently available NNRTIs and
other antiretroviral agents. The NNRTIs, along with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), are important
components of the combination regimens currently used to treat HIV-1
infection. The NRTIs/NtRTIs act by competing with the natural nucleotide
substrates of reverse transcriptase for incorporation into viral DNA
and subsequent chain termination. By contrast, the NNRTIs bind to an
allosteric site of the enzyme and disrupt the DNA polymerase function by
inducing conformational changes to the catalytic site. The allosteric
binding nature of NNRTIs generally results in improved safety profile
since there is no known human homolog for the drug-binding site of
the enzyme.
As with other NNRTIs, etravirine has
many drug–drug interactions. It is a substrate of CYP3A4, CYP2C9,
and CYP2C19, an inducer of 3A4, and an inhibitor of 2C9 and 2C19.
Caution should be used with co-administration of inducers, inhibitors, or
substrates of these enzymes. Etravirine can be synthesized starting from
5-bromo-2,4,6-trichloropyrimidine through three successive nucleophilic
substitution reactions. Initial displacement with 4-aminobenzonitrile using
Hu¨nig’s base, followed by reaction with sodium salt of 4-hydroxy-3,5-
dimethylbenzonitrile, and subsequent ammonolysis reaction with ammonia in dioxane under pressure affords etravirine.
.
Chemical Properties
White to Off-White Solid
Uses
Etravirine is an antiretroviral (anti-HIV) drug that is part of the non nucleoside reverse transcriptase inhibitor (NNRTIs or Non Nukes) family. It is used together with other antiretrovirals in treatment-experienced adult patients, who have failed previous therapy, and have HIV-1 strains which are resistant to other retrovirals and NNRTIs. Etravirine is used to delay the progression of HIV infection. By using etravirine, your immune system should improve (increase in CD4 + count) and you will be better protected against opportunistic infections.
Etravirine does not cure AIDS or completely kill the HIV virus, but helps to prevent further damage by slowing down the production of new viruses. Treatment with etravirine does not reduce the risk of passing infection on to others. You will still be able to pass HIV by sexual contact, by blood transfer or by sharing needles. You should always use appropriate precautions to prevent passing HIV on to others.
Definition
ChEBI: An aminopyrimidine that consists of 2,6-diaminopyrimidine bearing a bromo substituent at position 5, a 4-cyano-2,6-dimethylphenoxy substituent at position 4 and having a 4-cyanophenyl substituent attached to the 2-amino group. NNRTI of HIV-1, binds directl to RT and blocks RNA-dependent and DNA-dependent DNA polymerase activities
Acquired resistance
Various mutations are associated with a decreased virological response. Single codon substitutions at positions 100, 101 and 181 are considered major mutations. A single K103N mutation is not associated with resistance.
Pharmaceutical Applications
A comprehensive analysis of baseline resistance data from the DUET-1 and DUET-2 studies has identified a list of 17 etravirine resistance associated mutations: V901, A98G, L100L, K101E/H/I, V1061, E138A, V179D/F/T, Y181C/L/V, G190A/S, and M230L. A single K103N mutation is not associated with resistance to etravirine.
Mechanism of action
Etravirine binds directly to reverse transcriptase and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. Etravirine does not inhibit the human DNA polymerases alpha, beta, and gamma.
Pharmacokinetics
Oral absorption: Not known/available
Cmax 200 mg oral twice daily: c. 959 ng/mL
Cmin 200 mg oral twice daily: c. 469 ng/mL
Plasma half-life: c. 36 h
Volume of distribution: Not known/available
Plasma protein binding: >99%
Administration with food improves the bioavailability and
reduces interpatient variability. It undergoes oxidative metabolism
by cytochrome P450 systems. Around 93.7% and 1.2%
of an administered dose can be retrieved in the feces and
urine, respectively, mostly as unchanged drug.
Details of distribution into CSF, semen and breast milk
and recommendations for dose adjustment in patients with
hepatic impairment are not yet available.
Clinical Use
Treatment of HIV-1 infection in adults (in combination with other antiretroviral drugs)
Side effects
In the phase III studies around 15% of patients experienced
erythematous or maculopapular rashes of mild or moderate
severity; most resolved with continued dosing, but treatment
was discontinued in 2% of patients. Rare cases of Stevens–
Johnson syndrome have been reported.
Other common adverse events are diarrhea, nausea, headache
and fatigue. Dyslipidemia and raised pancreatic amylase
occur in some patients.
Etravirine Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Apotex Pharmachem India Pvt Ltd | +91-8022891034 +91-8022891000 | Karnataka, India | 109 | 58 | Inquiry |
| Laurus Labs Ltd | +91-4066594333 +91-4039804333 | Telangana, India | 50 | 58 | Inquiry |
| Arene Lifesciences Limited | +91-9849847907 +91-8455241148 | Telangana, India | 55 | 58 | Inquiry |
| Mylan Laboratories Ltd | +91-4023550543 +91-4030866666 | Telangana, India | 150 | 58 | Inquiry |
| HETERO LABS LTD | (630) 931-6800 | New Delhi, India | 97 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Online Med Export Solution | 09096386920 | Nagpur, India | 1 | 58 | Inquiry |
| LEE PHARMA LIMITED | +91-40-23770338 | New Delhi, India | 35 | 58 | Inquiry |
| J. Duncan HealthCare Private Limited | 09987634401 | Maharashtra, India | 3 | 58 | Inquiry |
| Angel Bio Pharma | 08069013898Ext 347 | Ahmedabad, India | 50 | 58 | Inquiry |
Related articles
- Uses and side effects of Etravirine
- Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)....
- Apr 19，2022
269055-15-4(Etravirine)Related Search:
1of4
chevron_right